Conference Reports for NATAP

EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom  April 9-13 Back

2 HIV/HCV Coinfection Studies at EASL       EASL: USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 INFECTION IN PATIENTS COINFECTED WITH HIV (Interim results) - (04/10/14) phase 2, 59 study participants   EASL: EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY - (04/11/14) NIH group, mostly African-Americans, 22-38% fibrosis stage 3   -----------------------   EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 9-13